Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications

Diabetes and Metabolism

Volumn 28, Issue 4 I, 2002, Pages 297-304

  Letellier, C ^a   Durou, M R ^a   Jouanolle, A M ^a   Le Gall, J Y ^a   Poirier, J Y ^a   Ruelland, Annie ^a  

^a Laboratoire de Biochimie   (France)

Author keywords

High density lipoprotein; Paraoxonase; Polymorphism; Type 2 diabetes mellitus; Vascular complications

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; VASCULAR DISEASE;

ADULT; ALLELES; ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DNA PRIMERS; ESTERASES; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 0036737786     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Steinberg DA, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med, 198, 320, 915-924.
2. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscl Thromb, 1996, 16, 831-842.
3. Klimov AN, Gurevich VS, Nikiforova A, et al. Antioxidative activity of high-density lipoprotein in vivo. Atherosclerosis, 1993, 100, 13-18.
4. Parthasarathy S. Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta, 1990, 1044, 275-283.
5. La Du BN. The human serum paraoxonase/arylesterase polymorphism (editorial). Am J Hum Genet, 1988, 43, 227-229.
6. Mackness MI, Mackness B, Durrington PN, Connely PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol, 1996, 7, 69-76.
7. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high-density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest, 1995, 96, 2882-2891.
8. Mackness MI, Walker CH, Carlson LA. Low A esterase activity in serum of patients with fish eye disease. Clin Chem, 1987, 35, 587-588.
9. Mackness MI, Peuchant E, Dumon M-F, Walker CH, Clerc M. Absence of "A" esterase activity in serum of patients with Tangier disease. Clin Biochem, 1989, 22, 475-478.
10. Humbert R, Adler DA, Disteche CM, Hassett HC, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet, 1993, 3, 73-76.
11. 1) was one member of a multigen family. Genomics, 1996, 33, 498-507.
12. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase gene is a risk factor for coronary artery disease. J Clin Invest, 1995, 96, 3005-3008.
13. Zama T, Mucata M, Matsubara Y, et al. A 192 Arg variant of the human paraoxonase gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol, 1997, 17, 3561-3569.
14. 2) were associated with the risk of coronary heart disease. Am J Hum Genet, 1998, 62, 36-44.
15. 1 55 and 192 polymorphism and paraoxonase activity and concentration in non insulin dependent diabetes mellitus. Atherosclerosis, 1998, 139, 341-349.
16. Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI. Low paraoxonase activity in type 2 diabetes mellitus complicated by retinopathy. Clin Science, 2000, 98, 355-363.
17. Ruiz J, Blanche H, James RW et al. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. The Lancet. 1995, 346, 869-872.
18. Pfohl M, Koch M, Enderle MD, et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease and myocardial infarction in type 2 diabetes. Diabetes, 1999, 48, 623-627.
19. Ikeda Y, Suehiro T, Inoue M, Nakauchi T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metab Clin Exp, 1998, 47, 598-602.
20. Ko YL, Doanghue K, Chan A, Knight J and Silink M. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab, 83, 2589-2592.
21. Antikainen M, Murtomäki S, Syvänne M, et al. The Gln-Arg 191 polymorphism of human paraoxonase gene is not associated with the risk of coronary artery disease in Finns. J Clin Invest, 1996, 98, 883-885.
22. Hermann SM, Blanc H, Poirier O, Cambien F. The Gln/arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis, 1996, 126, 299-303.
23. National diabetes data group. Classification and diagnostic of diabetes mellitus and other categories of glucose tolerance. Diabetes, 1979, 38, 183-185.
24. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem, 1972, 18, 499-502.
25. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoproteins against lipid peroxidation. Lancet, 1997, 349, 851-852.
26. Cao HB, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res, 1999, 40, 133-139.
27. Pfohl M, Koch M, Enderle MD, Kuhn R, et al. Paraoxonase 192 Gln/Arg gene polymorphism coronary artery disease and myocardial infarction in type II diabetes. Diabetes, 1999, 48. 623-627.
28. Imai Y, Morita H, Kurihara H, Sugiyama T, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerosis diseases. Atherosclerosis, 2000, 149, 435-442.
29. Gardemann A, Philippe M, Heb K, Katz N, et al. The paraoxonase Leu-Met 54 and Gln-Arg 191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis, 2000, 152, 421-431.
30. Garin MC, James RW, Dussoix P, Blanche H, et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest, 1997, 99, 62-66.
31. Malin R, Laine S, Rantalaiho V, Lehtimaki T, et al. Lipid peroxidation is increased in paraoxonase L55 homozygotes comparatively M allele carriers. Free Radic Res, 2001, 34, 477-484.
32. 2 gene at 7q 21-3: cloning, multiples mRNA forms and missense polymorphisms in the coding sequence. Gene, 1998, 213, 149-157.